XOMA Royalty (XOMA) Net Income towards Common Stockholders (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Net Income towards Common Stockholders came in at $4.5 million in Q1 2026, up 88.64% year-on-year from $2.4 million in Q1 2025, and up 117.22% quarter-over-quarter from -$25.9 million in Q4 2025.
XOMA Royalty (XOMA) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Net Income towards Common Stockholders across 16 years of filings, most recently posting $4.5 million for Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at $4.5 million, up 88.64% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.0 million (up 67.45% YoY), and the FY2025 annual result was -$320000.0, down 105.72% from the prior year.
- Net Income towards Common Stockholders came in at $4.5 million for Q1 2026 at XOMA Royalty, up from -$25.9 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $14.1 million in Q3 2025 to a low of -$25.9 million in Q4 2025.
- The 5-year median for Net Income towards Common Stockholders is -$5.8 million (2023), against an average of -$5.6 million.
- Across the five-year window, Net Income towards Common Stockholders plunged 392.49% in 2023 and jumped 181.49% in 2025, its largest moves.
- XOMA Royalty's Net Income towards Common Stockholders stood at -$6.2 million in 2022, then slumped by 221.0% to -$19.9 million in 2023, then jumped by 149.09% to $9.8 million in 2024, then slumped by 364.99% to -$25.9 million in 2025, then surged by 117.22% to $4.5 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $4.5 million (Q1 2026), -$25.9 million (Q4 2025), and $14.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | XOMA Royalty | 5.48 Mn | -60.60 Mn | - | 4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.47 Mn |
| Dec 31, 2025 | -25.93 Mn |
| Sep 30, 2025 | 14.05 Mn |
| Jun 30, 2025 | 1.37 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 9.79 Mn |
| Sep 30, 2024 | -17.24 Mn |
| Jun 30, 2024 | -13.48 Mn |
| Mar 31, 2024 | -10.56 Mn |
| Dec 31, 2023 | -19.93 Mn |
| Sep 30, 2023 | -5.79 Mn |
| Jun 30, 2023 | -5.96 Mn |
| Mar 31, 2023 | -10.17 Mn |
| Dec 31, 2022 | -6.21 Mn |
| Sep 30, 2022 | -4.37 Mn |
| Jun 30, 2022 | -4.77 Mn |
| Mar 31, 2022 | -2.07 Mn |
| Dec 31, 2021 | 29.86 Mn |
| Sep 30, 2021 | -4.44 Mn |
| Jun 30, 2021 | -2.24 Mn |